Spero Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 26, 2026

Rhea-AI Summary

Spero Therapeutics (Nasdaq: SPRO) said it will report fourth quarter and full year 2025 financial results and provide a business update on Thursday, March 26, 2026, after market close. The company noted it does not intend to host a conference call for the release.

Investors should expect a written release and related materials on that date rather than a live audio briefing.

Key Figures

Milestone payment: $25 million Q3 2025 net loss: $7.4 million Q3 2025 revenue: $5.4 million +5 more

8 metrics

Milestone payment $25 million Triggered by GSK tebipenem HBr NDA resubmission, expected Q1 2026

Q3 2025 net loss $7.4 million Quarter ended September 30, 2025

Q3 2025 revenue $5.4 million Down from $13.5 million year-ago quarter

Cash & equivalents $48.6 million Balance at September 30, 2025; management expects runway into 2028

Overall success rate 58.5% vs 60.2% PIVOT-PO Phase 3 primary endpoint vs IV imipenem-cilastatin

Clinical cure rate 93.5% vs 95.2% PIVOT-PO Phase 3 clinical cure outcome

Microbiological response ≈60% both arms PIVOT-PO Phase 3 microbiological outcome

Short interest 2.18% Reported short interest as a percent of float

Market Reality Check

Price: $2.46 Vol: Volume 385,784 is 21% abo...

normal vol

$2.46 Last Close

Volume Volume 385,784 is 21% above the 20-day average of 319,560 ahead of the earnings date announcement. normal

Technical Shares trade above the 200-day MA at $2.35, with the stock at $2.58 pre-announcement.

Peers on Argus

SPRO slipped 0.39% while peers were mixed: ATOS up 10.24%, ZNTL up 1.87%, ARMP, ...

SPRO slipped 0.39% while peers were mixed: ATOS up 10.24%, ZNTL up 1.87%, ARMP, HLVX, and MGNX down between 0.48% and 1.28%, indicating stock-specific trading rather than a unified sector move.

Historical Context

5 past events · Latest: Dec 19 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 19	Regulatory milestone	Positive	+1.3%	GSK resubmitted NDA for tebipenem HBr, triggering a $25M milestone.
Nov 28	Equity compensation	Neutral	+3.0%	Inducement grant of 90,000 RSUs to a new employee under equity plan.
Nov 13	Quarterly earnings	Positive	-1.2%	Q3 2025 results with positive PIVOT-PO data and reduced net loss.
Nov 04	Earnings date set	Neutral	+3.4%	Announcement of Q3 2025 earnings date and decision not to host a call.
Oct 21	Clinical trial data	Positive	+3.5%	Phase 3 PIVOT-PO met primary endpoint and was stopped early for efficacy.

Pattern Detected

Positive clinical and regulatory milestones have generally seen modest positive alignment, while fundamental quarter results have produced at least one negative divergence.

Recent Company History

Over the last six months, SPRO has advanced tebipenem HBr with positive Phase 3 PIVOT-PO data and an NDA resubmission by GSK, including a $25 million milestone tied to the filing. Quarterly updates showed a narrower Q3 2025 net loss and cash of $48.6 million, alongside discontinued non-core programs. Prior earnings-date announcements, like the Q3 2025 call timing, triggered modest gains. Today’s scheduling of Q4 and full-year 2025 results continues that cadence of regular operational updates.

Market Pulse Summary

This announcement sets the timing for Spero’s Q4 and full-year 2025 results, following a year marked...

Analysis

This announcement sets the timing for Spero’s Q4 and full-year 2025 results, following a year marked by positive PIVOT-PO Phase 3 data and an NDA resubmission that triggers a $25 million milestone. Prior filings highlighted lower revenue but a narrower net loss and cash of $48.6 million. Investors may focus on tebipenem HBr progress, updated cash runway, and any changes in strategic dependence on this lead asset during the upcoming update.

AI-generated analysis. Not financial advice.

CAMBRIDGE, Mass., March 18, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and diseases with high unmet need, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2025, and provide a business update on Thursday, March 26, 2026, after market close. The Company does not intend to host a conference call.

About Spero Therapeutics
Spero Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and diseases with high unmet need. For more information, visit www.sperotherapeutics.com.

Investor Relations Contact:
Shai Biran, PhD
Spero Therapeutics
IR@Sperotherapeutics.com

Media Inquiries: 
media@sperotherapeutics.com

FAQ

When will Spero Therapeutics (SPRO) release its Q4 and full-year 2025 results?

Spero will release Q4 and full-year 2025 results on March 26, 2026 after market close. According to the company, the announcement will include a business update but no live conference call, so materials will be posted following market close.

Will Spero Therapeutics (SPRO) hold a conference call for the March 26, 2026 update?

No, Spero does not intend to host a conference call for the March 26 update. According to the company, results and the business update will be provided in a release and posted materials rather than an audio webcast.

How can investors access Spero Therapeutics (SPRO) financial results on March 26, 2026?

Investors can access results via the company's posted release and investor materials after market close on March 26, 2026. According to the company, no live call will occur, so the investor relations site will host the written information.

What should shareholders expect in Spero Therapeutics' (SPRO) March 26, 2026 business update?

Shareholders should expect a written business update accompanying Q4 and full-year 2025 financial results after market close. According to the company, the update will summarize recent clinical and corporate developments without a live Q&A session.

What time will Spero Therapeutics (SPRO) publish its March 26, 2026 results relative to markets?

Spero will publish its Q4 and full-year 2025 results after market close on March 26, 2026. According to the company, the timing means the release follows U.S. market hours and will be available later that day on its investor site.